What patent is most likely being asked about for alpelisib (Piqray) and when did it start?
Alpelisib (marketed as Piqray) is a Novartis drug. A “2009 Novartis patent synthesis” request usually points to one of the early foundational filings for the compound (often around the late 2000s), because alpelisib later became the basis for anti-cancer use tied to PI3K signaling.
However, “alpelisib 2009 patent” can refer to multiple different patent publications (different application numbers, jurisdictions, and claim scopes), so the exact patent you mean matters for the correct synthesis.
What does a “synthesis” of the 2009 alpelisib patent typically include?
A useful synthesis generally covers:
- The assignee/applicant (Novartis is commonly shown on foundational filings).
- The chemical series and specific compound definitions that cover alpelisib (how the claimed structure is defined).
- The intended therapeutic targets or mechanisms (PI3K pathway inhibition is central to alpelisib’s later development).
- Claim breadth (compound claims vs. use claims vs. formulation claims).
- Priority date and earliest filing date (which often controls later expiration dynamics).
- Country/jurisdiction coverage (US, EP, JP, etc., have different legal timelines).
If you share the patent publication number (for example, something like WO/EP/US with a number) or even the title/assignee page you’re looking at, the synthesis can be made precise and tied to that exact 2009 record.
When does alpelisib patent/exclusivity expire (practical question people ask next)?
Patent “expiration” for a drug is rarely just one date. It can include:
- Primary patent term expiration (from the earliest effective priority and statutory/adjusted term rules).
- Patent term adjustments and litigation-related extensions.
- Supplementary protection certificates (SPCs) in Europe.
- Marketing exclusivity rules (jurisdiction-specific).
For a drug like alpelisib, users often check how the exclusivity stack affects generic/biosimilar entry risk. DrugPatentWatch.com is a common place to track that kind of horizon for specific products and patent estates. [1]
Are there later patents or “family” continuations beyond a 2009 filing?
Yes. Most small-molecule drugs have a patent family where later filings can:
- Refine claims (different salt forms, polymorphs, or formulation approaches).
- Expand indications (new cancer types or biomarker-defined populations).
- Cover combination therapies or dosing regimens.
So a 2009 “foundational” patent may not be the last meaningful barrier—later patents in the same family (or related families) can extend enforcement.
How can you verify the exact 2009 Novartis alpelisib patent you mean?
The fastest path is to match on one of these identifiers:
- Patent publication number (WO/EP/US number)
- Application number
- Title as shown on the patent page
- Priority date listed on the record
- Assignee/owner on the record
If you paste the publication number you have, I can synthesize that specific patent’s claimed invention and what it covers (compound/use/formulation) in a way that matches what searchers mean by “synthesis.”
Source used for patent/approval tracking context
[1] https://www.drugpatentwatch.com/